BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

RXBIO — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Report (No Activity)

RXBIO

via ASSET & EQUITY CORPORATION

4th Quarter (Oct 1 - Dec 31) · 2022Posted Sept 14, 2023Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: RXBIO
Description: A pharmaceutical company focused on development of healthcare/treatment technology
Location: Tennessee · United States of America

Registrant

Firm: ASSET & EQUITY CORPORATION
Description: Lobbying
Location: Knoxville,, Tennessee, United States of America

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.